Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
Abstract KRAS-specific inhibitors have shown promising antitumor effects, especially in non-small cell lung cancer, but limited efficacy in colorectal cancer (CRC) patients. Recent studies have shown that EGFR-mediated adaptive feedback mediates primary resistance to KRAS inhibitors, but the other r...
Saved in:
Main Authors: | Kohei Maruyama, Yuki Shimizu, Yumi Nomura, Tomoko Oh-hara, Yuki Takahashi, Satoshi Nagayama, Naoya Fujita, Ryohei Katayama |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-024-00793-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01) -
Role of silent mutations in KRAS-mutant tumors
by: Jun Lu, et al.
Published: (2025-02-01) -
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
by: Maximilian Kramer‐Drauberg, et al.
Published: (2025-02-01) -
A short history of »Kras«
by: Andrej Kranjc
Published: (2018-12-01) -
Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
by: Han Koo, et al.
Published: (2025-01-01)